The U.S. Food and Drug Administration (FDA) on Tuesday said its preliminary review has not found evidence that glucagon-like peptide-1 receptor agonists, commonly known as GLP-1 RAs, cause suicidal thoughts or actions.

Current prescribing information for GLP-1 drugs, including Eli Lilly and Co.’s (NYSE:LLY) and Novo Nordisk A/S‘ (NYSE:NVO) drugs, approved for weight management already includes warnings about suicidal thoughts and actions.

Though the agency on Tuesday said it continues to study the issue due to limited data and the seriousness of the concern.

In a safety update, the FDA said it reviewed reports submitted to the FDA Adverse Event Reporting System involving ...